Dr. Andrej Egorov received his MD and PhD in St. Petersburg, Russia. The initial topic of his carrier was research and development of the live cold-adapted attenuated influenza vaccine. From 1996 he has been working as professor at the Institute of Applied Microbiology in Vienna, Austria. In 1998 he published his key results http://www.ncbi.nlm.nih.gov/pubmed/9658085 describing influenza NS1 protein truncated mutants defective in interferon antagonizing function. Following research http://www.ncbi.nlm.nih.gov/pubmed/9878611;http://www.ncbi.nlm.nih.gov/pubmed/15542655 ; http://www.ncbi.nlm.nih.gov/pubmed/16971432 was addressed to the development of a new generation of live influenza vaccine and vectors with manipulated NS1 gene. From 2006 - VP Research, Avir Green Hills Biotechnology AG, Austria. Since 2012 Egorov is a founder and CSO of an Austrian startup company developing attenuated influenza vaccine vectors.
back to speakers